16 Apr 2024 • A recent study comparing sodium-glucose cotransporter type 2 inhibitors (SGLT2i) and sulfonylureas as second-line therapies in type 2 diabetes (T2D) patients on metformin monotherapy revealed significant advantages for SGLT2i.

SGLT2i initiation was associated with a lower risk of incident gout, major adverse cardiovascular events (MACE), and heart failure compared to sulfonylureas. Additionally, SGLT2i users also experienced fewer recurrent gout flares.

These findings offer valuable insights in optimizing treatment strategies for T2D patients, particularly those at risk of or with gout.

Source: JAMA | Read full story